...
首页> 外文期刊>Cancer immunology research. >Melanoma Induces, and Adenosine Suppresses, CXCR3-Cognate Chemokine Production and T-cell Infiltration of Lungs Bearing Metastatic-like Disease
【24h】

Melanoma Induces, and Adenosine Suppresses, CXCR3-Cognate Chemokine Production and T-cell Infiltration of Lungs Bearing Metastatic-like Disease

机译:黑色素瘤诱导和腺苷抑制,CXCR3聚集趋化因子的产生和肺转移性疾病的T细胞浸润。

获取原文
获取原文并翻译 | 示例
           

摘要

Despite immunogenicity, melanoma-specific vaccines have demonstrated minimal clinical efficacy in patients with established disease but enhanced survival when administered in the adjuvant setting. Therefore, we hypothesized that organs bearing metastatic-like melanoma may differentially produce T-cell chemotactic proteins over the course of tumor development. Using an established model of metastatic-like melanoma in lungs, we assessed the production of specific cytokines and chemokines over a time course of tumor growth, and we correlated chemokine production with chemokine receptor-specific T-cell infiltration. We observed that the interferon (IFN)-inducible CXCR3-cognate chemokines (CXCL9 and CXCL10) were significantly increased in lungs bearing minimal metastatic lesions, but chemokine production was at or below basal levels in lungs with substantial disease. Chemokine production was correlated with infiltration of the organ compartment by adoptively transferred CD8(+) tumor antigen-specific T cells in a CXCR3- and host IFN gamma-dependent manner. Adenosine signaling in the tumor microenvironment (TME) suppressed chemokine production and T-cell infiltration in the advanced metastatic lesions, and this suppression could be partially reversed by administration of the adenosine receptor antagonist aminophylline. Collectively, our data demonstrate that CXCR3-cognate ligand expression is required for efficient T-cell access of tumor-infiltrated lungs, and these ligands are expressed in a temporally restricted pattern that is governed, in part, by adenosine. Therefore, pharmacologic modulation of adenosine activity in the TME could impart therapeutic efficacy to immunogenic but clinically ineffective vaccine platforms.
机译:尽管具有免疫原性,但黑色素瘤特异性疫苗在已确诊疾病的患者中已显示出最低的临床疗效,但在佐剂环境中给药时可提高生存率。因此,我们假设携带转移性黑色素瘤的器官可能在肿瘤发展过程中差异产生T细胞趋化蛋白。使用已建立的肺转移样黑色素瘤模型,我们评估了肿瘤生长过程中特定细胞因子和趋化因子的产生,并将趋化因子的产生与趋化因子受体特异性T细胞浸润相关联。我们观察到干扰素(IFN)诱导的CXCR3同源趋化因子(CXCL9和CXCL10)在带有最小转移灶的肺中显着增加,但是在有实质性疾病的肺中趋化因子的产生达到或低于基础水平。趋化因子的产生与器官隔室的浸润相关,该器官隔室通过以CXCR3和宿主IFNγ依赖方式过继转移CD8(+)肿瘤抗原特异性T细胞而产生。肿瘤微环境(TME)中的腺苷信号传导抑制了晚期转移灶中趋化因子的产生和T细胞浸润,并且通过施用腺苷受体拮抗剂氨茶碱可以部分逆转这种抑制作用。总体而言,我们的数据表明CXCR3相关配体表达是肿瘤浸润的肺部有效T细胞进入所必需的,并且这些配体以时间受限的模式表达,该模式部分受腺苷控制。因此,TME中腺苷活性的药理学调节可以赋予免疫原性但临床上无效的疫苗平台以治疗功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号